Literature DB >> 3937231

Treatment failure in acute streptococcal tonsillitis in children over the age of 10 and in adults.

K Roos, S E Holm, C Ekedahl.   

Abstract

13/169 outpatients (8%) with streptococcal tonsillitis developed a new tonsillitis with the same strain within 2 weeks of completion of therapy (clinical treatment failures) and 24 (14%) remained carriers (bacterial treatment failures) after treatment with phenoxymethylpenicillin (penicillin V) 12.5 mg/kg body weight twice daily for 10 days. The mean serum concentration 60 min after penicillin V administration was 7.84 micrograms/ml. Very large individual differences in serum concentration were found but these differences could not be correlated to treatment failure. About 60% of the patients showed salivary concentrations around 0.03 micrograms/ml. Three strains of streptococci (groups C and G) from patients with bacterial treatment failure had MIC values of 0.06 and 0.12 micrograms/ml. A majority of the patients with clinical treatment failures had contact with individuals with high carrier rates of beta-hemolytic streptococci. It therefore seems likely that some so-called treatment failures in reality are new infections. In clinical treatment failures group A streptococci were twice as common as groups C + G. In bacteriological treatment failures the ratio between A and C + G was 1:1. Patients with nonstreptococcal tonsillitis as well as carriers of groups C and G may appear among bacterial treatment failures.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3937231     DOI: 10.3109/13813458509058775

Source DB:  PubMed          Journal:  Scand J Infect Dis        ISSN: 0036-5548


  2 in total

1.  Concentration of phenoxymethylpenicillin in tonsillar tissue.

Authors:  K Roos; J E Brorson
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

Review 2.  Penicillin tolerance and treatment failure in group A streptococcal pharyngotonsillitis.

Authors:  G J van Asselt; R P Mouton; C P van Boven
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-02       Impact factor: 3.267

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.